|
|
|
European Biopharmaceutical Review
|
|
Biosimilars, or ‘follow-on biologics’ as they are known in the US, provide access to affordable and effective medicines to patients around the world. Although the regulatory pathway put forward by the European Medicines Agency (EMEA) has facilitated the launch of a number of biosimilars, the market is still considered to be in a nascent stage. Estimates from IMS Health suggest that products worth $25 billion are expected to go off-patent by 2017, creating a significant opportunity for biosimilar players.
This article aims to set out the key challenges facing biosimilar market participants, in addition to various factors driving and restraining market growth. It also provides an overview of the competitive landscape of the current biosimilars industry and market trends.
THE ROLE OF BIOSIMILARS IN CONTROLLING PHARMACEUTICAL EXPENDITURE
One of the biggest problems facing developed economies around the world is the increase in per capita healthcare spending, which surpasses per capita income in several cases. As Figure 1 indicates, this trend is unsustainable in the long-run, and most governments have begun to take measures to ensure that spending growth falls in line with per capita income. Pharmaceutical expenditure, which is a critical component of healthcare budgets across the world, is being widely recognised as an area that needs to be controlled. This is precisely where generics and biosimilars have a crucial role to play. According to the European Generic medicines Association (EGA), generic medicines have made major contributions to affordable and accessible healthcare for over 20 years, saving the EU an estimated €20 billion annually. by 2017, creating a significant opportunity for biosimilar players. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Sumanth Kambhammettu is a Programme Leader with the European Healthcare Practice of Frost & Sullivan. He focuses on analysing trends in the pharmaceutical and biotechnology markets. He has worked on various consulting projects and research reports in the areas of CNS, women’s health, cardiovascular therapeutics, generics and biosimilars, pricing and reimbursement issues, speciality pharma, stem cells, contract manufacturing organisations and several other issue-based topics. In addition, he is a regular contributor of articles on market related issues to leading industry journals. Prior to joining Frost & Sullivan, Sumanth had worked as a marketing executive with Baxter India’s renal division. Sumanth holds a B-Pharm (Hons) from the Birla Institute of Technology & Sciences (BITS), Pilani. |
|
|
|
|
|
 |
News and Press Releases |
 |
Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round
Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing
single cell analysis systems underpinned by its patented picodroplet
technology, announced today that it has closed an additional tranche of
investment of $2.9 million (£2.2 million), securing a total of $4.8
million (£3.7 million) in investment. The funding will be used as
working capital for the Company’s Cyto-Mine® Single Cell Analysis
System, expansion of the UK facility and enable the doubling of
personnel through the opening of a new US Sales Office and Demo Lab in
California.
More info >> |
|
 |
White Papers |
 |
|
Overcoming research challenges with Adaptive Trials
PCI Pharma Services
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
More info >> |
|
 |
Industry Events |
 |
PDA Europe Annual Meeting 2019
24 June 2019, Hilton Amsterdam
Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >> |
|
|
